🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05479721
Active, not recruiting Observational

LITMUS Imaging Study

NCT05479721 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2019-09-04
Last updated
2025-04-16

Condition(s) studied

NAFLDNASHNASH - Nonalcoholic SteatohepatitisFibrosis, LiverSteatosis of Liver

Study summary

The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: 1. Recruited to the European NAFLD Registry 2. Patient had a liver biopsy less than 3 months prior to enrolment into the study or is having a liver biopsy in less than 3 months' time for the assessment of NAFLD. 3. Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: 1. Patients that do not speak the language in which the patient information is written will be excluded. Due to the nature of the study, being able to read the information about the study or access to a relevant interpreter is a necessary criterion for participant's safety in regards to MR scanning. 2. Patients judged by the investigator to be unsuitable for inclusion in the study (e.g. where the investigator feels that the participant will not be able to comply with the study procedures) 3. Any contra-indication to Magnetic Resonance Imaging (MRI) (e.g. ferrous metal implants/fragments, implantable cardiac defibrillator or permanent pacemaker, metal clips following neurosurgery, pregnancy, other condition that would make MR scanning unsafe in the opinion of the scanner operator)

Primary outcome measure(s)

Trial sites (18)

FacilityCityRegionStatus
Pinnacle Clinical Research San Antonio Texas
Helsinki University Hospital Helsinki Finland
Le Centre de Recherche Clinique (CRC) du CHU d'Angers Angers France
Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière Paris France
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz Mainz Germany
Universitätsklinikums Würzburg Würzburg Germany
Laiko General Hospital of Athens Athens Greece
Università di Palermo Palermo Italy
Department of Medical Sciences University of Torino Torino Italy
Vall d'Hebron University Hospital Barcelona Spain
Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital Seville Spain
HU Clínico de Valladolid Valladolid Spain
Linköping University Hospital Linköping Sweden
Inselspital, University Hospital Bern Switzerland
Addenbrookes Hospital Cambridge United Kingdom
The Newcastle Upon Tyne Hospitals Nhs Foundation Trust Newcastle upon Tyne United Kingdom
Queens Medical Centre Nottingham United Kingdom
Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom

More University of Oxford trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05479721 on ClinicalTrials.gov ↗ ← All trials in Germany